Chapter 21:

LEARNING OBJECTIVES

On completion of the chapter, the reader will be able to:

1. Characterize the epidemiologic difference between ulcerative colitis (UC) and Crohn’s disease (CD).
2. Discuss the proposed etiologies underlying the development of inflammatory bowel disease (IBD).
3. Describe the differences in disease distribution and major pathophysiologic findings between UC and CD.
4. Explain the common extraintestinal manifestations associated with IBD.
5. Describe the typical clinical presentation of UC and CD, including how to gauge disease severity.
6. Formulate treatment goals and expected outcomes for management of patients with active IBD.
7. Discuss the role of nutritional and surgical interventions in the management of patients with IBD.
8. Explain the pharmacologic options for medical induction of remission in patients with active IBD.
9. Recommend appropriate pharmacologic treatment for maintenance of remission of IBD.
10. Discuss the major toxicities associated with pharmacologic agents used in the treatment of IBD.
11. Construct an appropriate monitoring plan for evaluating the efficacy and toxicity of drug therapies for IBD.
12. Differentiate how the treatment of IBD is altered in pregnant patients.